In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo

International Journal of Pharmaceutics

Volumn 335, Issue 1-2, 2007, Pages 138-146

  Leonard, Alexis Kays ^a   Sileno, Anthony P ^a   Brandt, Gordon C ^a   Foerder, Charles A ^a   Quay, Steven C ^a   Costantino, Henry R ^a  

^a Nastech Pharmaceutical Company Inc   (United States)

Author keywords

Formulation; Galantamine; In vitro in vivo correlation; Nasal drug delivery; Pharmacokinetics

Indexed keywords

EDETIC ACID; EXCIPIENT; GALANTAMINE; LEVO ALPHA PHOSPHATIDYLCHOLINE DIDECANOYL; METHYL BETA CYCLODEXTRIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG PENETRATION; FERRET; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; NONHUMAN; NOSE MUCOSA; PRIORITY JOURNAL; RAT; RETCHING; VOMITING;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; CELL MEMBRANE PERMEABILITY; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMPOUNDING; EDETIC ACID; ELECTRIC IMPEDANCE; EPITHELIAL CELLS; EXCIPIENTS; FACTOR ANALYSIS, STATISTICAL; FERRETS; GALANTAMINE; HUMANS; PHOSPHATIDYLCHOLINES; RATS; RATS, SPRAGUE-DAWLEY; RESPIRATORY MUCOSA; TIGHT JUNCTIONS; VOMITING;

EID: 33947577597     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.11.013     Document Type: Article

References (63)

1. Ahmed S., Sileno A.P., deMeireles J.C., Dua R., Pimplaskar H.K., Xia W.J., Marinaro J., Langenback E., Matos F.J., Putcha L., Romeo V.D., and Behl C.R. Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. Pharm. Res. 17 (2000) 974-977
2. Ahsan F., Arnold J., Meezan E., and Pillion D.J. Enhanced bioavailability of calcitonin formulated with alkylglycosides following nasal and ocular administration in rats. Pharm. Res. 18 (2001) 1742-1746
3. 2EDTA, and aprotinin on rectal, nasal, and buccal insulin delivery. Pharm. Res. 5 (1988) 305-308
4. Bagger M.A., Nielsen H.W., and Bechgaard E. Nasal bioavailability of peptide T in rabbits, absorption enhancement by sodium glycocholate and glycofurol. Eur. J. Pharm. Sci. 14 (2001) 69-74
5. Carstens S., Danielsen G., Guldhammer B., and Frederiksen O. Transport of insulin across rabbit nasal mucosa in vitro induced by didecanoyl-l-alpha-phosphatidylcholine. Diabetes 42 (1993) 1032-1040
6. Cassidy M., and Tidball C. Cellular mechanism of intestinal permeability alterations produced by chelation depletion. J. Cell Biol. 32 (1967) 685-698
7. Chen S.-C., Eiting K., Cui K., Kays Leonard A., Morris D., Li C.-Y., Farber K., Sileno A.P., Houston M.E., Johnson P.H., Quay S.C., and Costantino H.R. Therapeutic utility of a novel tight junction modulating peptide for enhancing intranasal drug delivery. J. Pharm. Sci. 95 (2006) 1364-1371
8. Cicinelli E., Cignarelli M., Petruzzi D., Matteo M.G., Ruccia C., and Schonauer L.M. Nasal spray vs. oral administration of bromocriptine, pharmacology and effect on serum prolactin in puerperal women. J. Endocrinol. Invest. 19 (1996) 427-432
9. Coates P.A., Ismail I.S., Luzio S.D., Griffiths I., Ollerton R.L., Volund A., and Owens D.R. Intranasal insulin, the effects of three dose regimens on postprandial glycaemic profiles in type II diabetic subjects. Diab. Med. 12 (1995) 235-239
10. Davis S.S., and Illum L. Absorption enhancers for nasal drug delivery. Clin. Pharmacokinet. 42 (2003) 1107-1128
11. Dimova S., Brewster M.E., Noppe M., Jorissen M., and Augustijns P. The use of human nasal in vitro cell systems during drug discovery and development. Toxicol. In Vitro 19 (2005) 107-122
12. Evans J.G., Wilcock G., and Birks J. Evidence-based pharmacotherapy of Alzheimer's disease. Int. J. Neuropsychopharmacol. 7 (2004) 351-369
13. Hasegawa M., Sasaki T., Sadakane K., Tabuchi M., Takeda Y., Kimura M., and Fujii Y. Studies for the emetic mechanisms of ipecac syrup (TJN-119) and its active components in ferrets, involvement of 5-hydroxyptamine receptors. Jpn. J. Pharmacol. 89 (2002) 113-119
14. Hosoya K., Kubo H., Natsume H., Sugibayashi K., and Morimoto Y. Evaluation of enhancers to increase nasal absorption using Ussing chamber technique. Biol. Pharm. Bull. 17 (1994) 316-322
15. Hosoya K., Kubo H., Natsume H., Sugibayashi K., and Morimoto Y. Evaluation of bile acids and fusidate derivative as nasal absorption enhancers using an electrophysiological technique. Biol. Pharm. Bull. 22 (1999) 1089-1093
16. Hussain A.A. Intranasal drug delivery. Adv. Drug Deliv. Rev. 29 (1998) 39-49
17. Hussain M.A., and Aungst B.J. Intranasal absorption of oxymorphone. J. Pharm. Sci. 86 (1997) 975-976
18. Illum L., Farraj N.F., and Davis S.S. Chitosan as a novel nasal delivery system for peptide drugs. Pharm. Res. 11 (1994) 1186-1189
19. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci. 11 (2000) 1-18
20. Illum L., Watts P., Fisher A.N., Hinchcliffe M., Norbury H., Jabbal-Gill I., Nankervis R., and Davis S.S. Intranasal delivery of morphine. J. Pharmacol. Exp. Ther. 301 (2002) 391-400
21. Illum L. Nasal drug delivery-possibilities, problems and solutions. J. Control. Rel. 87 (2003) 187-198
22. Illum L. Is nose-to-brain transport of drugs in man a reality?. J. Pharm. Pharmacol. 56 (2004) 3-17
23. Jann M.W., Shirley K.L., and Small G.W. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin. Pharmacokinet. 41 (2002) 719-739
24. Johnson P.H., and Quay S.C. Advances in nasal drug delivery through tight junction technology. Expert. Opin. Drug Deliv. 2 (2005) 281-298
25. Kays Leonard A., Sileno A.P., MacEvilly C., Foerder C.A., Quay S.C., and Costantino H.R. Development of a novel high-concentration galantamine formulation suitable for intranasal delivery. J. Pharm. Sci. 94 (2005) 1736-1746
26. Knox A.P., Strominger N.L., Battles A.H., and Carpenter D.O. Behavioral studies in emetic sensitivity in the ferret. Brain Res. Bull. 31 (1993) 477-484
27. Laursen T., Grandjean B., Jorgensen J.O., and Christiansen J.S. Bioavailability and bioactivity of three different doses of nasal growth hormone (GH) administered to GH-deficient patients, comparison with intravenous and subcutaneous administration. Eur. J. Endocrinol. 135 (1996) 309-315
28. Marttin E., Romeijn S.G., Verhoeff J.C., and Merkus F.W. Nasal absorption of dihydroergotamine from liquid and powder formulations in rabbits. J. Pharm. Sci. 86 (1997) 802-807
29. Marttin E., Verhoef J.C., and Merkus F.W. Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs. J. Drug Target. 6 (1998) 17-36
30. Mason S., Penton H., and Mansell P. The ferret as a model of emetic sensitivity (2004), Society of Toxicology Meeting, Baltimore, MD
31. Matsubara K., Abe K., Irie T., and Uekama K. Improvement of nasal bioavailability of luteinizing hormone-releasing hormone agonist, buserelin, by cyclodextrin derivatives in rats. J. Pharm. Sci. 84 (1995) 1295-1300
32. Mente S.R., and Lombardo F. A recursive-partitioning model for blood-brain barrier permeation. J. Comp.-Aid. Mol. Des. 19 (2005) 465-481
33. Merkus F.W., Verhoef J.C., Romeijn S.G., and Schipper N.G. Absorption enhancing effect of cyclodextrins on intranasally administered insulin in rats. Pharm. Res. 8 (1991) 588-592
34. Mitra R., Pezron I., Chu W.A., and Mitra A.K. Lipid emulsions as vehicles for enhanced nasal delivery of insulin. Int. J. Pharm. 205 (2000) 127-134
35. Monbaliu J., Verhaeghe T., Willems B., Bode W., Lavrijsen K., and Meuldermans W. Pharmacokinetics of galantamine, a cholinesterase inhibitor, in several animal species. Arzneimittelforschung 53 (2003) 486-495
36. Mustafa F., Yang T., Khan M.A., and Ahsan F. Chain length-dependent effects of alkylmaltosides on nasal absorption of enoxaparin. J. Pharm. Sci. 93 (2004) 675-683
37. Nakamura K., Maitani Y., and Takayama K. The enhancing effect of nasal absorption of FITC-dextran 4400 by beta-sitosterol beta-d-glucoside in rabbits. J. Control. Rel. 79 (2002) 147-155
38. Natsume N.H., Iwata S., Ohtake K., Miyamoto M., Yamaguchi M., Hosoya K., Kobayashi D., Sugibayashi K., and Morimoto Y. Screening of cationic compounds as an absorption enhancer for nasal drug delivery. Int. J. Pharm. 185 (1999) 1-12
39. Ohtake K., Natsume H., Ueda H., and Morimoto Y. Analysis of transient and reversible effects of poly-l-arginine on the in vivo nasal absorption of FITC-dextran in rats. J. Control. Rel. 82 (2002) 263-275
40. Olivier J.C., Djilani M., Fahmy S., and Couet W. In situ nasal absorption of midazolam in rats. Int. J. Pharm. 213 (2001) 187-192
41. Pillion D.J., Ahsan F., Arnold J.J., Balusubramanian B.M., Piraner O., and Meezan E. Synthetic long-chain alkyl maltosides and alkyl sucrose esters as enhancers of nasal insulin absorption. J. Pharm. Sci. 91 (2002) 1456-1462
42. Pontiroli A.E. Peptide hormones: review of current and emerging uses by nasal delivery. Adv. Drug Deliv. Rev. 29 (1998) 81-87
43. Prego C., Garcia M., Torres D., and Alonso M.J. Transmucosal macromolecular drug delivery. J. Control Rel. 101 (2005) 151-162
44. Reynolds J.A., Tanford C., and Stone W.L. Interaction of l-a-didecanoyl phosphatidylcholine with the AI polypeptide of high density lipoprotein. Proc. Natl. Acad. Sci. 74 (1997) 3796-3799
45. Romeo V.D., deMeireles J.C., Gries W.J., Xia W.J., Sileno A.P., Pimplaskar H.K., and Behl C.R. Optimization of systemic nasal drug delivery with pharmaceutical excipients. Adv. Drug Deliv. Rev. 29 (1998) 117-133
46. Röpke M., Unmack M.A., Willumsen N.J., and Frederiksen O. Comparative aspects of actions of a short-chain phospholipid on epithelial Na + channels and tight junction conductance. Comp. Biochem. Physiol. 118A (1997) 211-214
47. Rudd J.A., Jordan C.C., and Naylor R.J. Profiles of emetic action of cisplatin in the ferret, a potential model of acute and delayed emesis. Eur. J. Pharmacol. 262 (1994) R1-R2
48. Rudy A.C., Coda B.A., Archer S.M., and Wermeling D.P. A multiple-dose phase I study of intranasal hydromorphone hydrochloride in healthy volunteers. Anesth. Analog. 99 (2004) 1379-1386
49. Sam T.S.W., Kan K.K.W., Ngan M.P., Rudd J.A., and Yeung J.H.K. Action of metyrapone and tetracosactrin to modify cisplatin-induced acute and delayed emesis in the ferret. Eur. J. Pharmacol. 466 (2003) 163-168
50. Sayani A.P., and Chien Y.W. Systemic delivery of peptides and proteins across absorptive mucosae. Crit. Rev. Ther. Drug Carrier Syst. 13 (1996) 85-184
51. Schipper N.G., Romeijn S.G., Verhoef J.C., and Merkus F.W. Nasal insulin delivery with dimethyl-beta-cyclodextrin as an absorption enhancer in rabbits, powder more effective than liquid formulations. Pharm. Res. 10 (1993) 682-686
52. Scott L.J., and Goa K.L. Galantamine, a review of its use in Alzheimer's disease. Drugs 60 (2000) 1095-1122
53. Song Y., Wang Y., Thakur R., Meidan V.M., and Michniak B. Mucosal drug delivery: membranes, methodologies, and applications. Crit. Rev. Ther. Drug Carrier Syst. 21 (2004) 195-256
54. Sramek J.J., Frackiewicz E.J., and Cutler N.R. Review of the acetylcholinesterase inhibitor galanthamine. Expert. Opin. Investig. Drugs 9 (2000) 2393-2402
55. Strickley R.G. Solubilizing excipients in oral and injectable formulations. Pharm. Res. 21 (2004) 201-230
56. Turiiski V.I., Krustev A.D., Sirakov V.N., and Getova D.P. In vivo and in vitro study of the influence of the anticholinesterase drug galantamine on motor and evacuative functions of rat gastrointestinal tract. Eur. J. Pharmacol. 498 (2004) 233-239
57. Turker S., Onur E., and Ozer Y. Nasal route and drug delivery systems. Pharm. World Sci. 26 (2004) 137-142
58. Vermehren C., Johansen P.B., and Hansen H.S. Absorption and metabolism of the absorption enhancer didecanoylphophatidylcholine in rabbit nasal epithelium in vivo. Drug Metabol. Dispos. 25 (1997) 1083-1088
59. Wang J., Sakai S., Deguchi Y., Bi D., Tabata Y., and Morimoto K. Aminated gelatin as a nasal absorption enhancer for peptide drugs, evaluation of absorption enhancing effect and nasal mucosa perturbation in rats. J. Pharm. Pharmacol. 54 (2002) 181-188
60. Wearley L.L. Recent progress in protein and peptide delivery by non-invasive routes. Crit. Rev. Ther. Drug Carrier Syst. 8 (1991) 331-394
61. Yamahita M., Yamashita M., Tanaka J., Chagi K., Takeda S., Kurihara T., Takeda Y., and Fujii Y. Vomiting induction by ipecac syrup in dogs and ferrets. J. Toxicol. Sci. 22 (1997) 409-412
62. Youdim K.A., Avdeef A., and Abbott N.J. In vitro trans-monolayer permeability calculations, often forgotten assumptions. Drug Disc. Today 8 (2003) 997-1003
63. Yu S., Zhao Y., Wu F., Zhang X., Lu W., Zhang H., and Zhang Q. Nasal insulin delivery in the chitosan solution, in vitro and in vivo studies. Int. J. Pharm. 281 (2004) 11-23